|
Title
|
|
|
|
Management of patients with malignancy before heart transplantation
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background: Heart transplantation and malignancy connect in several ways. Cancer can be an incidental finding, cancer treatment can also be the cause of end-stage heart failure, for which heart transplantation is necessary or malignancy can occur after transplantation, because of immune suppression. Methods: This is a database search on Web of Science from 2010 on, with the term “heart transplant* AND (cancer OR malignancy)”. This resulted in 3767 titles. Results: Eight articles contained sufficient information about survival. In most series, a history of pre-transplant malignancy (PTM) did not affect survival, except for hematologic malignancy or short cancer-free pre-transplant interval. Other patient-related factors were usually more important. The effect of PTM on the rate of post-transplant malignancy followed a comparable pattern. In patients with chemotherapy-related cardiomyopathy, other causes than malignancy were more important. Conclusions: The outcome for heart transplantation in patients with PTM is acceptable in terms of survival, and occurrence post-transplant malignancy. An appropriate PTM-free interval of two to five years seems necessary. Hematologic PTM has a worse outcome. Although the limitations of this review warrant caution with the interpretation of its results, increased post-transplant screening for malignancy and of use of proliferation signal inhibitors, due to their antineoplastic activity, could be cornerstones of the management of these patients. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
International journal of cardiology and lipidology research
| |
|
Publication
|
|
|
|
2020
| |
|
DOI
|
|
|
|
10.15379/2410-2822.2020.06.02.01
| |
|
Volume/pages
|
|
|
|
6
:2
(2020)
, p. 1-7
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|